Research opportunities in clinical research
Our funding schemes accept research across the clinical and translational pipeline, as well as supporting clinical academic careers.
We support a broad portfolio of clinical and translational research through response mode funding, initiatives and investments in clinical infrastructure.
We aim to maximise patient benefit through high-impact early phase and first-in-human trials, ambitious and innovative trial designs, and our core-funded supporting infrastructure, which together enable us to learn as much as we can from the patients on our trials.
We're also committed to ensuring that clinical academics have the support they need to develop a career in cancer research, and we have a range of opportunities for clinical researchers at all career levels.
Our overarching aims are to maintain a broad portfolio of clinical research that maximises patient impact, and to learn as much as we can from the patients on our trials.
We have set out our priorities, and how we intend to achieve them, in our clinical research statement of intent, which is used as a basis for strategic discussion by the Clinical Research Committee.
Our research strategy
We invest in creative people who can deliver research of the highest quality. Our strategy shapes how we'll discover more about the mechanisms of how cancer develops and progresses to unlock new and better ways to prevent, detect and treat it.
Our clinical portfolio
Our broad portfolio of clinical trials and associated research spans treatment modalities and disease sites. Explore some recent highlights from our clinical portfolio in the case studies below.
Stan Kaye has devoted his career to bringing new drugs into the clinic and turning the UK into a drug development powerhouse. In 2016 we awarded him the CRUK Lifetime Achievement Prize.
Dr Geoff Higgins, a CRUK Clinician Scientist and an Honorary Consultant Clinical Oncologist specialising in the management of lung cancer, shared his experiences of applying for his fellowship.
Professor Francesca Demichelis has assembled a team to develop the sensitivity of liquid biopsies as a clinical tool for prostate cancer management.
Please email: email@example.com